Dentons advises Bpifrance Large Venture on oversubscribed US$75 million Series C financing of Adcendo ApS

"Dentons advised Bpifrance Large Venture on the oversubscribed US$75 million Series C financing of Danish biotech Adcendo ApS. New investors included Jeito Capital, Vida Ventures, Bpifrance Large Venture and EIFO, with participation from existing investors such as RA Capital, TPG, OrbiMed, Venrock and Novo Holdings. Proceeds will fund multiple ADC clinical programs and upcoming milestones."

Dentons represented Bpifrance Large Venture in the oversubscribed US$75 million Series C financing of Danish-headquartered global biotech company Adcendo ApS. The financing round, which closed at US$75 million and was oversubscribed, attracted new investors Jeito Capital, Vida Ventures, Bpifrance Large Venture and EIFO. All existing investors also participated, including TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital. Proceeds from the Series C will support Adcendo’s advancement of a pipeline of first‑ and best‑in‑class antibody‑drug conjugate (ADC) programs through multiple upcoming clinical milestones. Planned development activities include the ADCE‑T02 (Tissue Factor ADC) Phase I Tiffany‑01 cohort expansion across several high unmet‑need tumor indications; the ADCE‑D01 (uPARAP) ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other cancers of mesenchymal origin; and the ADCE‑B05 dose escalation study in squamous cell carcinomas. Dentons represented Bpifrance Large Venture with a team composed by: Olivia Guéguen, partner; Laura Godard, counsel; and Lisa Morand, associate.

Menu

Dentons advises Bpifrance Large Venture on oversubscribed US$75 million Series C financing of Adcendo ApS

Read the full story

Menu

Dentons advises Bpifrance Large Venture on oversubscribed US$75 million Series C financing of Adcendo ApS

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads